Stay updated on Safety of CVL-231 in Schizophrenia: Clinical Trial
Sign up to get notified when there's something new on the Safety of CVL-231 in Schizophrenia: Clinical Trial page.

Latest updates to the Safety of CVL-231 in Schizophrenia: Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check38 days agoChange DetectedThe study has reduced its locations from 97 to 85, with significant changes in the geographical areas covered, including the removal of several locations in the United States and Bulgaria. Additionally, the study contact information has been removed.SummaryDifference13%
- Check45 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check53 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check67 days agoChange DetectedA new withdrawal has been noted for Julie Adams at AbbVie, with the last update posted on January 10, 2025, while the status for Erica Koenig at Cerevel Therapeutics has been removed, indicating a shift in recruitment status.SummaryDifference1%
- Check74 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in this functionality.SummaryDifference0.2%
Stay in the know with updates to Safety of CVL-231 in Schizophrenia: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of CVL-231 in Schizophrenia: Clinical Trial page.